US 2017/0319560 A1 · PYRAZOLE, TRIAZOLE AND TETRAZOLE OREXIN RECEPTOR ANTAGONISTS

Abstract

The present invention is directed to pyrazole, triazole and tetrazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the pyrazole, triazole, and tetrazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

A compound of the formula I:

wherein:
X is N or C(R7);
Y is N or C(R6), wherein when Y is N then X is also N;
A is selected from the group consisting of phenyl, naphthyl and heteroaryl;
R1a, R1b and R1c are independently selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) hydroxyl,
(4) —(C═O)m—On—C1-6alkyl, where m is 0 or 1, n is 0 or 1 (wherein if m is 0 or n is 0, a bond is present) and where the alkyl is unsubstituted or substituted with one or more sub stituents selected from R4,
(5) —(C═O)m—On—C3-6cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents selected from R4,
(6) —(C═O)m—C2-4alkenyl, where the alkenyl is unsubstituted or substituted with one or more substituents selected from R4,
(7) —(C═O)m—C2-4alkynyl, where the alkynyl is unsubstituted or substituted with one or more substituents selected from R4,
(8) —(C═O)m—On-phenyl or —(C═O)m—On-naphthyl, where the phenyl or naphthyl is unsubstituted or substituted with one or more substituents selected from R4,
(9) —(C═O)m—On-heterocycle, where the heterocycle is unsubstituted or substituted with one or more substituents selected from R4,
(10) —(C═O)m—NR10R11, wherein R10 and R11 are independently selected from the group consisting of:
(a) hydrogen,
(b) C1-6alkyl, which is unsubstituted or substituted with R4,
(c) C3-6alkenyl, which is unsubstituted or substituted with R4,
(d) C3-6alkynyl, which is unsubstituted or substituted with R4,
(e) C3-6cycloalkyl which is unsubstituted or substituted with R4,
(f) phenyl, which is unsubstituted or substituted with R4, and
(g) heterocycle, which is unsubstituted or substituted with R4,
(11) —S(O)2—NR10R11,
(12) —S(O)q—R12, where q is 0, 1 or 2 and where R12 is selected from the definitions of R10 and R11,
(13) —CO2H,
(14) —CN, and
(15) —NO2;
R3 is selected from C1-6alkyl and C3-6cycloalkyl, which is unsubstituted or substituted with one or more substituents selected from R4;
R4 is selected from the group consisting of:
(1) hydroxyl,
(2) halogen,
(3) C1-6alkyl,
(4) —C3-6cycloalkyl,
(5) —O—C1-6alkyl,
(6) —O(C═O)—C1-6alkyl,
(7) —NH2,
(7) —NH—C1-6alkyl,
(8) —NO2,
(9) phenyl,
(10) heterocycle,
(11) —CO2H, and
(12) —CN;
R5 is selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) C1-6alkyl, which is unsubstituted or substituted with halogen, hydroxyl, —O—C1-6alkyl, —NH2, —NH—Cl-6alkyl, —(C═O)O—C1-6alkyl, or phenyl, wherein the phenyl is unsubstituted or substituted with C1-6alkyl, halogen, or C1-6alkyl-OH,
(4) C3-6cycloalkyl, which is unsubstituted or substituted with C1-6alkyl, halogen, hydroxyl, —O—C1-6alkyl, —NH2, —NH—C1-6alkyl, —(C═O)O—C1-6alkyl, or phenyl, wherein the phenyl is unsubstituted or substituted with C1-6alkyl, halogen, or C1-6alkyl-OH,
(5) —O—C1-6alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and
(6) —(C═O)O—C1-6alkyl,
(7) —CN,
(8) —(C═O)NH2,
(9) —(C═O)NH—C1-6alkyl, and
(10) —(C═O)NH—O—C1-6alkyl;
R6 is selected from the group consisting of:
(1) hydrogen,
(2) halogen,
(3) C1-6alkyl, which is unsubstituted or substituted with halogen, hydroxyl, —O—C1-6alkyl, —NH2, —NH—C1-6alkyl, —(C═O)O—C1-6alkyl, or phenyl, wherein the phenyl is unsubstituted or substituted with C1-6alkyl, halogen, or C1-6alkyl-OH,
(4) C3-6cycloalkyl, which is unsubstituted or substituted with C1-6alkyl, halogen, hydroxyl, —O—C1-6alkyl, —NH2, —NH—C1-6alkyl, —(C═O)O—C1-6alkyl, or phenyl, wherein the phenyl is unsubstituted or substituted with C1-6alkyl, halogen, or C1-6alkyl-OH,
(5) —O—C1-6alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and
(6) —(C═O)O—C1-6alkyl,
(7) —CN,
(8) —(C═O)NH2,
(9) —(C═O)NH—C1-6alkyl, and
(10) —(C═O)NH—O—C1-6alkyl;
R7 is selected from the group consisting of:
(1) hydrogen and
(2) C1-6alkyl, or
a pharmaceutically acceptable salt thereof.

65 more elements

Pyrazole, triazole and tetrazole orexin receptor antagonists

Life of this patent

Pyrazole, triazole and tetrazole orexin receptor antagonists

Life of this patent

Abstract

Claims21